Literature DB >> 22772304

Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.

O Chillag-Talmor1, N Giladi, S Linn, T Gurevich, B El-Ad, B Silverman, N Friedman, C Peretz.   

Abstract

The aim of this work was to estimate in an incident cohort of pharmacy-based PD patients the survival of men and women accounting for age at treatment initiation and to compare their gender-specific survival with that of the general Israeli population. A population-based cohort of 4,848 incident pharmacy-based PD cases with definite/probable/possible certainty was previously identified using a drug-tracer approach for 1999-2008. Survival analysis was performed for two time scales: survival after treatment initiation (disease duration), and life-time survival (life expectancy). Kaplan-Meier curves and Cox regressions were used to compare survival across gender. Gender-specific SMRs were calculated from national rates and were compared using Poisson regression. During the follow-up from first purchase of any anti-parkinsonian drug (mean 4.0 ± 2.6 years, range 2 months-10 years), 1,266 (26 %) of the cases died. Younger age at first anti-parkinsonian drug purchase and female gender were associated with increased survival after treatment initiation (HR = 1.089, 95 % CI 1.080-1.098 for 1-year age increase; HR = 0.716, 95 % CI 0.640-0.800, females vs. males). Life-time survival increased with older age at first anti-parkinsonian drug purchase and female gender (HR = 0.759, 95 % CI 0.746-0.771 for 1-year age increase; HR = 0.694, 95 % CI 0.621-0.776, females vs. males). Sensitivity analysis on a sub-cohort of definite cases (n = 2501) yielded similar results. In comparison to the general Israeli population, mortality among pharmacy-based PD patients was significantly increased (SMR(men) = 1.69, 95 % CI 1.57-1.81, SMR(women) = 1.49, 95 % CI 1.37-1.62), differently between genders (p < 0.01). Female gender was associated with longer, perhaps more benign disease course, and longer life expectancy. Earlier age at anti-parkinsonian drug initiation increased disease duration, but was associated with shorter life expectancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772304     DOI: 10.1007/s00415-012-6584-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies.

Authors:  D Taeger; Y Sun; U Keil; K Straif
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

2.  What predicts mortality in Parkinson disease?: a prospective population-based long-term study.

Authors:  E B Forsaa; J P Larsen; T Wentzel-Larsen; G Alves
Journal:  Neurology       Date:  2010-10-05       Impact factor: 9.910

3.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

Review 4.  Gender disparities in Parkinson's disease.

Authors:  Lisa M Shulman; Viveca Bhat
Journal:  Expert Rev Neurother       Date:  2006-03       Impact factor: 4.618

5.  Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study.

Authors:  M Guttman; P M Slaughter; M E Theriault; D P DeBoer; C D Naylor
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

6.  Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.

Authors:  Honglei Chen; Shumin M Zhang; Michael A Schwarzschild; Miguel A Hernán; Alberto Ascherio
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

7.  Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.

Authors:  Mette Brandt-Christensen; Kajsa Kvist; Flemming Mørkeberg Nilsson; Per Kragh Andersen; Lars Vedel Kessing
Journal:  Mov Disord       Date:  2006-08       Impact factor: 10.338

8.  Survival study of Parkinson disease in Olmsted County, Minnesota.

Authors:  Alexis Elbaz; James H Bower; Brett J Peterson; Demetrius M Maraganore; Shannon K McDonnell; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  Arch Neurol       Date:  2003-01

Review 9.  Mild Parkinsonian signs: An overview of an emerging concept.

Authors:  Elan D Louis; David A Bennett
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

10.  Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population.

Authors:  Orly Chillag-Talmor; Nir Giladi; Shai Linn; Tanya Gurevich; Baruch El-Ad; Barbara Silverman; Nurit Friedman; Chava Peretz
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

  10 in total
  3 in total

1.  Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.

Authors:  Nir Giladi; Mahnaz Asgharnejad; Lars Bauer; Frank Grieger; Babak Boroojerdi
Journal:  J Parkinsons Dis       Date:  2016-04-02       Impact factor: 5.568

2.  Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study.

Authors:  Chava Peretz; Hagar Segev; Violet Rozani; Tanya Gurevich; Baruch El-Ad; Judith Tsamir; Nir Giladi
Journal:  Clin Neuropharmacol       Date:  2016 Sep-Oct       Impact factor: 1.592

3.  Prospective comorbidity-matched study of Parkinson's disease and risk of mortality among women.

Authors:  Anke C Winter; Pamela M Rist; Julie E Buring; Tobias Kurth
Journal:  BMJ Open       Date:  2016-09-26       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.